Benitec Biopharma Inc (BNTC) — Who Owns This Stock? 13F Breakdown (Q2 2026)

BNTC ranks #4852 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

89 institutions disclose a position in BNTC, but none treat it as a major bet — even Lion Point Capital, LP, its most concentrated holder, allocates just 4.0% of its own portfolio to it.

Simplify Asset Management Inc. has added to its BNTC position for two straight quarters, increasing it by $11.4M to reach $13.5M today.

Longaeva Partners L.P. has trimmed its BNTC position for two straight quarters, cutting it by $3.7M while still holding $199.0K.

BNTC is up 4.6% today, and institutions have been net buyers of $17.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

BNTC reported a net loss of $41.5M over the trailing twelve months.

• Not yet profitable — net loss of $41.5M over the trailing twelve months
• Net income declined year over year, from -$33.8M to -$41.5M
• Operating cash flow was negative, using $23.6M in cash
• Current ratio of 54.67x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.02x equity — within a conventional range